Advertisement

Topics

Generic Drug Price Slump's Latest Victim: Mylan's Profit Target

19:38 EDT 9 Aug 2017 | Topix

Mylan NV executives have gotten up in front of investors every year and said they could bet on one thing -- that the maker of generic drugs would hit at least $6 in earnings per share in 2018. On Wednesday, Mylan cut its adjusted earnings forecast for next year to $5.40 a share, sending the shares tumbling.

Original Article: Generic Drug Price Slump's Latest Victim: Mylan's Profit Target

NEXT ARTICLE

More From BioPortfolio on "Generic Drug Price Slump's Latest Victim: Mylan's Profit Target"

Quick Search
Advertisement
 

Relevant Topic

Generics Drugs
A generic drug (generic drugs, short: generics) is a drug defined as "a drug product that is comparable to brand/reference listed drug product in dosage form, strength, route of administration, quality and performance characteristics, and intended u...